ClinicalTrials.gg
Enrolling by invitationNCT06880042NB-UVBUpdated Jun 24, 2025

COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO

An Early Phase 1 interventional study of Tacrolimus and Calcipotriol in Vitiligo - Macular Depigmentation and Tacrolimus, sponsored by Dr ayesha wahid. Enrolling by invitation at 1 site in Pakistan. Open to participants aged 15 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-24.

Sponsored by Dr ayesha wahid · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
15 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing tacrolimus in Vitiligo — 2 open to participants now, 2 under way, none of them phase 3. Tacrolimus · Vitiligo.

Planned enrollment
5th of 10
60 · median 51
Started
2025
with 2 others
Phase 1
2 of 11
1 open now
Registered
9th of 11
by date
Lead sponsor
1 of 11
Dr ayesha wahid

Among the 11 studies testing tacrolimus in Vitiligo, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2025, is one of 2 in phase 1, and was the 9th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

2 of the 11 studies testing tacrolimus in Vitiligo are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tacrolimus

Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 15 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing tacrolimus in Vitiligo, or all of them as a file.
02

Study summary

Patient of stable and limited vitiligo less than 20% BSA will be recruited And evaluation of efficacy and safety of narrowband UVB with topical tacrolimus vs narrowband UVB and calcipotriol will be assessed

Read the detailed description

Evaulation of efficacy and safety of narrowband uvb and tacrolimus and NBUVB and calcipotriol in patient if stable vitiligo with body surface area less than 20% It will be assessed by VASI score and VIisual analogie scale

03

Conditions studied

  • Vitiligo - Macular Depigmentation
  • Tacrolimus

Browse trials for

Keywords

  • Vitiligo
04

Who can participate

Ages eligible
15 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Localized vitiligo Age 15 to 70years Body surface upto 20% Stable more than 3 months

Exclusion criteria

Exclusion Criteria:

    • Pregnant or lactating female patients.

      • Skin or any other malignant skin condition.
      • Photo induced or photo aggravated dermatosis like (SLE, photodermatitis, rosacea, psoriasis, pemphigus vulgaris) along with vitiligo.
      • Prior history of allergy to tacrolimus or calcipotriol.
      • Other form of treatment for vitiligo within at least 1 month.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Tacrolimus

    Patient of Limited vitiligo less than 20% BSA will be treated with topical tacrolimus and narrowband UVB

    Drug: Tacrolimus

  • Active comparator
    Calcipotriol

    Calcipotriol is a vitamin D analogue that will act as immunomodulator

    Drug: Calcipotriol

Interventions

  • Tacrolimus is calcineurin inhibitor that will act as immunomodulator

  • Calcipotriol is a vitamin D analogue that will act as immunomodulator

06

What researchers measure

Primary outcomes

  1. VASI improvement upto 50%

    Improvement in VASI score upto 50%

    Time frame: 3 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Jun 2025, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Mar 17, 2025
StartActual
May 1, 2025
Primary completionEst.
Jun 30, 2025
CompletionEst.
Aug 30, 2025
Last update
Jun 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06880042
Lead sponsor
Dr ayesha wahid
Responsible party
Dr ayesha wahid (Awahid, Lahore General Hospital) — Sponsor-investigator
First posted
Mar 17, 2025
Start date
May 1, 2025
Primary completion
Jun 30, 2025 (estimated)
Completion
Aug 30, 2025 (estimated)
Last update
Jun 24, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tacrolimus · Calcipotriene

Start the discussion